JP MORGAN/CALL/BOSTON SCIENTIFIC/85/0.1/16.01.26 | Real-time Bid/Ask 10:05:53 2024-07-02 EDT | ||
| 1.18 EUR / 1.2 EUR | -4.80% |
|
| 1 month | +4.17% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-07-02 | 1.2 | -4.00% |
| 24-07-01 | 1.25 | 0.00% |
| 24-06-28 | 1.25 | -0.79% |
| 24-06-27 | 1.26 | -3.08% |
| 24-06-26 | 1.3 | +4.00% |
Delayed Quote Börse Stuttgart
Last update July 02, 2024 at 02:59 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JK7JZB |
| ISIN | DE000JK7JZB7 |
| Date issued | 2024-04-04 |
| Strike | 85 $ |
| Maturity | 2026-01-16 (563 Days) |
| Parity | 10 : 1 |
| Emission price | 0.41 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.34 € |
|---|---|
| Lowest since issue | 0.84 € |
| Spread | 0.02 € |
| Spread % | 1.67% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
76.41
USD
Average target price
82.35
USD
Spread / Average Target
+7.78%
- Stock Market
- Warrants
- Warrant
